---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-007973"
form_type: "8-K"
ticker: "NTHI"
cik: "0001979414"
company_name: "NEONC TECHNOLOGIES HOLDINGS, INC."
filed_at: "2025-10-09T23:59:59+00:00"
generated_at: "2026-05-17T04:14:36.629494+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeOnc subsidiary NuroMENA signs MSA with M42's IROS for UAE Phase 2b/3 trial of NEO100; board expanded

## Summary
- MSA with IROS (affiliate of M42 and Mubadala) covers clinical research services in UAE for CNS cancer therapies.
- First work order: Phase 2b/3 study of intranasal NEO100 in progressive/recurrent GBM and Grade III astrocytomas.
- Estimated budget of $2.4M in service fees plus $0.1M pass-through costs, milestone-based payments.
- NuroMENA board expands with Waleed K. Al Ali (CEO of Quazar Investment) and its Chairman, alongside Amir Heshmatpour and others.
- Company retains all IP and data from studies under MSA; agreement governed by Abu Dhabi Global Market law.

## SEC filing metadata
- accession: 0001829126-25-007973
- form_type: 8-K
- ticker: NTHI
- cik: 0001979414
- company_name: NEONC TECHNOLOGIES HOLDINGS, INC.
- filed_at: 2025-10-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1979414/000182912625007973/0001829126-25-007973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1979414/000182912625007973/neonctechnologies_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-007973
- JSON: https://secwatch.observer/filing/0001829126-25-007973.json
- Plain text: https://secwatch.observer/filing/0001829126-25-007973.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.